James Groark

Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty‐Two–Week Randomized, Double‐Blind, Placebo‐Controlled Study

William Stohl, Andreas Schwarting, Masato Okada et al. · Arthritis & Rheumatology · 2017 · 417 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol

Y K Onno Teng, Ian N Bruce, Betty Diamond et al. · BMJ Open · 2019 · 111 citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +17

Phase <scp>III</scp>/<scp>IV</scp>, Randomized, <scp>Fifty‐Two</scp>–Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus

Ellen M. Ginzler, Luiz Sergio Guedes Barbosa, David D’Cruz et al. · Arthritis & Rheumatology · 2021 · 103 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: An 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies

Karen A. Tourian, S. Krishna Padmanabhan, James Groark et al. · Clinical Therapeutics · 2009 · 69 citations

Pharmacy, Pharmacology, Pharmacotherapy +13

Efficacy and Safety of Subcutaneous Belimumab in Anti–Double‐Stranded <scp>DNA</scp>–Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus

Andrea Doria, William Stohl, Andreas Schwarting et al. · Arthritis & Rheumatology · 2018 · 65 citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +14